Celldex Therapeutics
CLDX
Market cap $2.03B

30.65 USD

-0.19

0.62%

At close Oct 4, 4:00 PM EDT

After hours

30.65

+0.00

0%

1 day

-0.62%

5 days

-7.18%

1 month

-31.19%

3 months

-13.66%

6 months

-22.54%

Year to date

-24.15%

1 year

15.66%

5 years

1,325.58%

About: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Employees: 160

Healthcare In Vitro & In Vivo Diagnostic Substances

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 12 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

65% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 49

20% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]

2.58% less ownership

Funds ownership: 108.17% [Q1] → 105.59% (-2.58%) [Q2]

8% less funds holding

Funds holding: 196 [Q1] → 180 (-16) [Q2]

12% less capital invested

Capital invested by funds: $2.92B [Q1] → $2.58B (-$349M) [Q2]

41% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 39

80% less call options, than puts

Call options by funds: $3.39M | Put options by funds: $17M

See Fund Rankings

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$37

21%

upside

Avg. target

$66

114%

upside

High target

$80

161%

upside

12 analyst ratings

10 positive

83%

2 neutral

17%

0 negative

0%

Goldman Sachs Richard Law 75% 1-year accuracy 3 / 4 met price target	47%upside $45	Neutral Initiated	30 Sept 2024
HC Wainwright & Co. Joseph Pantginis 39% 1-year accuracy 79 / 205 met price target	161%upside $80	Buy Reiterated	26 Sept 2024
Wolfe Research Andy Chen 36% 1-year accuracy 4 / 11 met price target	66%upside $51	Outperform Reiterated	25 Sept 2024
Cantor Fitzgerald Kristen Kluska 100% 1-year accuracy 3 / 3 met price target	119%upside $67	Overweight Reiterated	20 Sept 2024
Cantor Fitzgerald Kristen Kluska 100% 1-year accuracy 3 / 3 met price target	119%upside $67	Overweight Reiterated	18 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about CLDX published over the past 30 days

Zacks Investment Research

CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.

CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

- 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across omalizumab-experienced/refractory/naïve disease - - Well tolerated through 52 weeks - - Enrollment to Global Phase 3 CSU trials underway - - Company to host webcast today at 12:00 pm ET/6:00 pm CEST -

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 being held in Amsterdam on September 25-28, 2024.

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

Celldex Therapeutics to Present at Upcoming Investor Conferences

HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:

Celldex Therapeutics to Present at Upcoming Investor Conferences

Zacks Investment Research

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

HAMPTON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients -

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics to Present at Jefferies Healthcare Conference

HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data further support barzolvolimab clinical benefit to patients with CSU -

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

See News Rankings

Charts implemented using Lightweight Charts™